Holtway Global Hedge Expands into Europe, Providing Exclusive Pre-IPO and IPO Access to Companies Led by Visionary Founders like Elon Musk and Sam Altman
European Investors Gain Unprecedented Entry to Leading Technology and Finance Pre-IPO Opportunities
LUXEMBOURG, LUXEMBOURG / ACCESSWIRE / November 2, 2024 / Holtway Global Hedge Pte. Ltd., a premier global wealth management firm with over €1 billion in assets under management, proudly announces its expansion into the European market. This strategic move provides European investors with unparalleled access to high-growth pre-IPO and IPO opportunities involving transformative sectors and notable assets like XRP, innovative technologies, and emerging leaders in space exploration, artificial intelligence, and blockchain development. Holtway Global Hedge is positioned to meet the growing demand for unique investment opportunities within Europe's dynamic financial markets.
"European investors are increasingly seeking access to high-potential pre-IPOs and IPOs," said Kian Tan, CEO of Holtway Global Hedge. "We're committed to offering them carefully vetted opportunities in transformative sectors such as blockchain, aerospace, and advanced technology. Our European expansion enables investors to participate in the growth of pre-IPO ventures led by renowned figures like Elon Musk, the visionary behind advanced space technologies and creator of products like Grok, and Sam Altman, known for pioneering innovations like ChatGPT."
Empowering Investors with High-Growth Potential Investments
Holtway Global Hedge's pre-IPO and IPO offerings allow European investors to invest in market-defining companies before they go public-an opportunity traditionally limited to institutional and U.S.-based investors. This includes access to companies involved with digital assets like XRP, and technologies shaping the future of finance, space exploration, and artificial intelligence.
Through a client-centric approach and comprehensive global market analysis, Holtway Global Hedge identifies opportunities in emerging industries, guiding investors through the complexities of pre-IPO and IPO investments. By focusing on innovative blockchain initiatives, pioneering space technology enterprises, and leaders in advanced sectors like AI and fintech, the firm connects clients with key players at the forefront of their respective industries.
Why Choose Holtway Global Hedge?
Exclusive Access: Gain entry to investment opportunities in high-demand sectors, including fintech, aerospace, artificial intelligence, blockchain, digital assets like XRP, and asset management.
Expert Insight: Leverage Holtway's extensive expertise, with over 40 financial advisors and partners collectively offering more than 250 years of wealth management experience.
Global Reach: Benefit from Holtway Global Hedge's international presence, supported by its headquarters in Singapore, a global operations office in Canada, and newly extended services across Europe.
About Holtway Global Hedge
Holtway Global Hedge is a global wealth management firm dedicated to empowering individuals and families to achieve financial freedom. With a focus on long-term growth, Holtway offers a diverse portfolio of wealth and investment services, specializing in access to pre-IPO and IPO markets worldwide.
Get Started with Holtway Global Hedge
For more information on pre-IPO and IPO opportunities, European investors are invited to visit HoltwayGlobal.com or contact our dedicated support team at info@holtwayglobal.com.
This release continues Holtway's legacy of offering exclusive investment options and emphasizes its growing presence in Europe, highlighting the firm's commitment to clients' financial success.
For further information on Holtway Global Hedge and its market insights, visit holtwayglobal.com or contact:
Media Contact:
Li Wei Tan
Director of Communications
Holtway Global Hedge
Email: media@holtwayglobal.com
Company Contact Information:
Holtway Global Hedge Pte. Ltd.
Phone: +65 3125 6069
Email: info@holtwayglobal.com
SOURCE: Holtway Global Hedge Pte. Ltd.
View the original press release on accesswire.com
Holtway Global Hedge Pte. Ltd.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
Datavault AI Expands IBM Collaboration to Deploy Enterprise-Grade AI at the Edge with Available Infrastructure's SanQtum AI Platform8.1.2026 13:00:00 CET | Press release
Datavault AI will activate a secured multi-city edge AI network for real-time data tokenization, security, and monetization across New York and Philadelphia NEW YORK, NY / ACCESS Newswire / January 8, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in instant data monetization & enterprise digital twins, announced it will deliver enterprise-grade AI performance at the edge in New York and Philadelphia through an expanded collaboration with IBM using the SanQtum AI platform. Operated by Available Infrastructure, SanQtum AI is a fleet of synchronized micro edge data centers running IBM's watsonx portfolio of AI products on a zero-trust network. The combined deployment is designed to enable cybersecure data storage and compute, real-time data scoring, tokenization, and ultra-low-latency, across two of the most data-dense metro regions in the United States. By running Datavault AI's Information Data Exchange and DataScore agents - built with watsonx - within SanQtum AI's zero-trust edge e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom